Table 2.
Summary Table of Univariate PFS Analysis for BRCA1 mRNA Expression Level in the Two Treatment Arms
| Variable | N | Stratified Kaplan-Meier Model |
Cox Regression |
|||
|---|---|---|---|---|---|---|
| PFS, Median (95% CI) | p Value | Contrast | HR (95% CI) | p Value | ||
| Gefitinib | ||||||
| BRCA1-low | 29 | 10.2 (9.2–16.7) | 0.0193 | BRCA1-high vs. BRCA1-low | 2.08 (1.11–3.91) | 0.0223 |
| BRCA1-high | 27 | 9.1 (7.1–12.0) | ||||
| Gefitinib plus olaparib | ||||||
| BRCA1-low | 22 | 10.9 (7.2–36.4) | 0.8755 | BRCA1-high vs. BRCA1-low | 0.94 (0.41–2.14) | 0.8749 |
| BRCA1-high | 25 | 14.6 (8.6–20.3) | ||||
CI, confidence interval; HR, hazard ratio; PFS, progression-free survival.